Neuronetics Q3 revenue misses estimates

Reuters11-04

Neuronetics Q3 revenue misses estimates

Overview

Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations
U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis
CEO Keith J. Sullivan to retire in June 2026, search for successor underway

Outlook

Company expects Q4 2025 revenue between $40 mln and $43 mln
Neuronetics revises 2025 revenue guidance to $147 mln-$150 mln
Company targets positive cash flow from operations in Q4 2025

Result Drivers

GREENBROOK ACQUISITION - Revenue growth primarily driven by Greenbrook clinic acquisition
PURCHASING PATTERNS - Decline in treatment session revenue due to changes in customer purchasing patterns
CASH MANAGEMENT - Improved cash management with reduced cash used in operations

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	$37.30 mln	$37.80 mln (3 Analysts)
Q3 EPS		-$0.13
Q3 Gross Margin		45.90%
Q3 Operating Expenses		$24.40 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Neuronetics Inc is $7.00, about 60.4% above its November 3 closing price of $2.77

Press Release: ID:nGNX3WbyNw

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2580736888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-04 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580736888","market":"nz","top_or_hot":-1,"title":"Neuronetics Q3 revenue misses estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Neuronetics Q3 revenue misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations</p></li><li><p>U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis</p></li><li><p>CEO Keith J. Sullivan to retire in June 2026, search for successor underway</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects Q4 2025 revenue between $40 mln and $43 mln</p></li><li><p>Neuronetics revises 2025 revenue guidance to $147 mln-$150 mln</p></li><li><p>Company targets positive cash flow from operations in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GREENBROOK ACQUISITION - Revenue growth primarily driven by Greenbrook clinic acquisition</p></li><li><p>PURCHASING PATTERNS - Decline in treatment session revenue due to changes in customer purchasing patterns</p></li><li><p>CASH MANAGEMENT - Improved cash management with reduced cash used in operations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$37.30 mln</p></td><td><p>$37.80 mln (3 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.13</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>45.90%</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$24.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Neuronetics Inc is $7.00, about 60.4% above its November 3 closing price of $2.77</p></li></ul><p>Press Release: <span>ID:nGNX3WbyNw</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuronetics Q3 revenue misses estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuronetics Q3 revenue misses estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-04 20:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Neuronetics Q3 revenue misses estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Neuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectations</p></li><li><p>U.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basis</p></li><li><p>CEO Keith J. Sullivan to retire in June 2026, search for successor underway</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects Q4 2025 revenue between $40 mln and $43 mln</p></li><li><p>Neuronetics revises 2025 revenue guidance to $147 mln-$150 mln</p></li><li><p>Company targets positive cash flow from operations in Q4 2025</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>GREENBROOK ACQUISITION - Revenue growth primarily driven by Greenbrook clinic acquisition</p></li><li><p>PURCHASING PATTERNS - Decline in treatment session revenue due to changes in customer purchasing patterns</p></li><li><p>CASH MANAGEMENT - Improved cash management with reduced cash used in operations</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>$37.30 mln</p></td><td><p>$37.80 mln (3 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.13</p></td><td></td></tr><tr><td><p>Q3 Gross Margin</p></td><td></td><td><p>45.90%</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$24.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the advanced medical equipment &amp; technology peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Neuronetics Inc is $7.00, about 60.4% above its November 3 closing price of $2.77</p></li></ul><p>Press Release: <span>ID:nGNX3WbyNw</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STIM","symbol_name":"Neuronetics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL1N3WG0JS:1","article_id":"2580736888","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580736888","pubTimestamp":1762258440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Neuronetics Q3 revenue misses estimatesOverviewNeuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectationsU.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basisCEO Keit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STIM":"Neuronetics Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4110":"抵押房地产投资信托","BK4082":"医疗保健设备","NLY":"Annaly Capital Management"},"translate_title":"Neuronetics第三季度收入未达预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NLY":0.9,"STIM":0.9},"content_text":"Neuronetics Q3 revenue misses estimatesOverviewNeuronetics Q3 2025 revenue rose 101% yr/yr but missed analyst expectationsU.S. Greenbrook clinic revenue grew 25% on an adjusted pro forma basisCEO Keith J. Sullivan to retire in June 2026, search for successor underwayOutlookCompany expects Q4 2025 revenue between $40 mln and $43 mlnNeuronetics revises 2025 revenue guidance to $147 mln-$150 mlnCompany targets positive cash flow from operations in Q4 2025Result DriversGREENBROOK ACQUISITION - Revenue growth primarily driven by Greenbrook clinic acquisitionPURCHASING PATTERNS - Decline in treatment session revenue due to changes in customer purchasing patternsCASH MANAGEMENT - Improved cash management with reduced cash used in operationsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMiss$37.30 mln$37.80 mln (3 Analysts)Q3 EPS-$0.13Q3 Gross Margin45.90%Q3 Operating Expenses$24.40 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 3 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the advanced medical equipment & technology peer group is \"buy\"Wall Street's median 12-month price target for Neuronetics Inc is $7.00, about 60.4% above its November 3 closing price of $2.77Press Release: ID:nGNX3WbyNwFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2580736888","isCrawlerRequest":true}